Walleye Capital’s Enliven Therapeutics ELVN Stock Holding History

Walleye Capital’s Portfolio ELVN Stock Details ELVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.48M	Buy	+37,827	New	+$1.05M	0.01%	1717
2024 Q4	–	Sell	-99,416	Closed	-$2.54M	–	5007
2024 Q3	$2.54M	Buy	+99,416	New	+$2.3M	0.01%	1730
2024 Q2	–	Sell	-56,763	Closed	-$998K	–	5689
2024 Q1	$998K	Buy	+56,763	New	+$871K	﹤0.01%	2591
2022 Q1	–	Sell	-19,295	Closed	-$174K	–	2367
2021 Q4	$174K	Sell	19,295 -22,619	-54%	-$297K	0.01%	1521
2021 Q3	$684	Buy	+41,914	New	+$871K	0.02%	644
2021 Q2	–	Sell	-8,426	Closed	-$284	–	1386
2021 Q1	$284	Buy	+8,426	New	+$428K	0.02%	804

Other funds holding ELVN

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Walleye Capital's ELVN Position: Q1 2026 in Review

Walleye Capital opened a new position in Enliven Therapeutics (ELVN) in Q1 2026: 37,827 shares worth $1.48M. The stake represents 0.01% of the portfolio and ranks #1717 among its holdings. This is a return to the name: Walleye Capital previously reported a position in ELVN as recently as Q3 2024.

Walleye Capital first reported a position in ELVN in Q1 2021 and has held it in 6 quarters since. The position peaked at $2.54M in Q3 2024. 170 funds tracked by Wall St. Rank hold ELVN as of Q1 2026.

Walleye Capital held 37,827 shares of Enliven Therapeutics worth $1.48M as of Q1 2026.
Enliven Therapeutics was a new Walleye Capital position in Q1 2026.
Enliven Therapeutics made up 0.01% of Walleye Capital's portfolio in Q1 2026, its #1717 holding.
Walleye Capital first reported a position in Enliven Therapeutics in Q1 2021 and has held it in 6 quarters since.
Walleye Capital's Enliven Therapeutics position peaked at $2.54M in Q3 2024.
170 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.